{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:26:59Z","timestamp":1777530419550,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T00:00:00Z","timestamp":1507075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Andalusian Regional Ministry of Health (Spain)."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The aim of this study was to analyze how the consumption of medication over time affects the survival rate in patients with a coronary event and whether there is a gender difference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The study included 804 patients admitted to 4 hospitals with a coronary event during 2007. Monitoring after coronary event was carried out during 2007 and every 6 months in the subsequent 2 years (2008 and 2009) throughout the review of the clinical history of the patient. The main outcome was the analysis of mortality after the coronary event. Kaplan-Meier survival curves were plotted to calculate the time to death, comparing women versus men for 4 medication groups: aspirin, statins, \u03b2-blockers, and angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers (ACEIs\/ARBs). A Cox regression model was used for the final mortality analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>During the follow-up time, 172 deaths were assessed. Each month of treatment with aspirin, statins, \u03b2-blockers, or ACEI\/ARB was associated with a decrease in mortality between 13.0% and 0.5% (univariate analysis). The Kaplan-Meier method revealed a significant reduction in mortality after the coronary event for each month of treatment with aspirin (men), statins (men), and \u03b2-blockers (both men and women). No significant effect in survival was observed in either gender with ACEI\/ARB treatment. The final multivariable model (Cox regression) showed that the taking of aspirin, statins, \u03b2-blockers, or ACEI\/ARB is able to reduce mortality rates up to 7.0% (aspirin) throughout each month of treatment after a coronary event without any influence of gender.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Aspirin, statins, \u03b2-blockers, and ACEI\/ARB revealed a protective character with each month of treatment throughout the follow-up period, in terms of risk reduction of death. Aspirin and statins showed the maximum benefit, followed by ACEI\/ARB and \u03b2-blockers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1074248417732833","type":"journal-article","created":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T21:34:02Z","timestamp":1507152842000},"page":"192-199","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Monthly Medication on Mortality After a Coronary Event"],"prefix":"10.1177","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3135-777X","authenticated-orcid":false,"given":"Mar\u00eda C.","family":"Montero-Balosa","sequence":"first","affiliation":[{"name":"Primary Care Pharmacy Service, Aljarafe-Sevilla Norte Primary Care District, Andalusian Health Service, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Fern\u00e1ndez-Urrusuno","sequence":"additional","affiliation":[{"name":"Primary Care Pharmacy Service, Aljarafe-Sevilla Norte Primary Care District, Andalusian Health Service, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"Vilches-Arenas","sequence":"additional","affiliation":[{"name":"Medical School, University of Seville, Seville, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,10,4]]},"reference":[{"key":"bibr1-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu299"},{"key":"bibr2-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b36"},{"key":"bibr3-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2011.07.010"},{"key":"bibr4-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.111.964700"},{"key":"bibr5-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1001\/2012.jama.11348"},{"key":"bibr6-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2011.09.009"},{"key":"bibr7-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7753(07)72497-1"},{"key":"bibr8-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-8932(10)70157-3"},{"key":"bibr9-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1016\/S0828-282X(06)70925-4"},{"key":"bibr10-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2012.10.014"},{"key":"bibr11-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.11.019"},{"key":"bibr12-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-8932(99)75004-9"},{"key":"bibr13-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1157\/13124991"},{"key":"bibr14-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1157\/13072471"},{"key":"bibr15-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.5.485"},{"key":"bibr16-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62070-X"},{"key":"bibr17-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1157\/13127230"},{"key":"bibr18-1074248417732833","unstructured":"V\u00e1zquez R, Michavila A, Barrera C, Proceso asistencial integrado Evento Coronario con elevaci\u00f3n del ST. Junta de Andaluc\u00eda. Consejer\u00eda de Salud, 2007, 2\u00aa edici\u00f3n: http:\/\/www.csalud.junta-andalucia.es\/salud\/export\/sites\/csalud\/galerias\/documentos\/p_3_p_3_procesos_asistenciales_integrados\/angina_infarto\/angina_infarto.pdf."},{"key":"bibr19-1074248417732833","unstructured":"SIGN 148. Acute coronary syndrome. A national clinical guideline. 2016. http:\/\/www.sign.ac.uk\/guidelines\/fulltext\/148\/index.html."},{"key":"bibr20-1074248417732833","unstructured":"NICE. Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease. Clinical guideline. 2013. https:\/\/www.nice.org.uk\/guidance\/cg172\/chapter\/1-Recommendations#drug-therapy-2."},{"key":"bibr21-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs075"},{"key":"bibr22-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.348"},{"key":"bibr23-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2011.05.011"},{"key":"bibr24-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-310705"},{"issue":"1","key":"bibr25-1074248417732833","first-page":"1","volume":"15","author":"Lopez A","year":"2007","journal-title":"Bolet\u00edn de Informaci\u00f3n Farmacoterap\u00e9utica de Navarra"},{"key":"bibr26-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"issue":"7","key":"bibr27-1074248417732833","first-page":"37","volume":"22","author":"Agirrezabala JR","year":"2014","journal-title":"Infac"},{"key":"bibr28-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr035"},{"key":"bibr29-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2014.03.010"},{"key":"bibr30-1074248417732833","doi-asserted-by":"publisher","DOI":"10.1186\/1475-9276-13-19"},{"key":"bibr31-1074248417732833","doi-asserted-by":"crossref","unstructured":"Mach\u00f3n M, Aldasoro E, Mart\u00ednez-Camblor P, Socioeconomic differences in incidence and relative survival after a first acute myocardial infarction in the Basque Country, Spain. Gac Sanit. 2012;26(1):16\u201323.","DOI":"10.1016\/j.gaceta.2011.06.013"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248417732833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1074248417732833","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248417732833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:42:42Z","timestamp":1777394562000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1074248417732833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,4]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1177\/1074248417732833"],"URL":"https:\/\/doi.org\/10.1177\/1074248417732833","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,4]]}}}